OOIR: Observatory of International Research

Papers

(The H4-Index of Drugs is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Prevention and Treatment of Monkeypox	342
BNT162b2 mRNA COVID-19 Vaccine: First Approval	237
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	206
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	198
Pharmaco-Immunomodulatory Therapy in COVID-19	196
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences	195
Inclisiran: First Approval	188
Lumasiran: First Approval	178
Remdesivir: First Approval	172
Nirmatrelvir Plus Ritonavir: First Approval	168
Casimersen: First Approval	154
Aducanumab: First Approval	137
Acute Pancreatitis: Diagnosis and Treatment	132
Sotorasib: First Approval	123
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I	107
Risdiplam: First Approval	105
TRPV1-Targeted Drugs in Development for Human Pain Conditions	101
Setmelanotide: First Approval	101
Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update	101
Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing	97
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	93
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects	91
Belantamab Mafodotin: First Approval	90
Selpercatinib: First Approval	90
Bulevirtide: First Approval	89

Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?	88
Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer	84
Orelabrutinib: First Approval	84
Inhaled Liposomal Antimicrobial Delivery in Lung Infections	82
Nivolumab Plus Relatlimab: First Approval	79
REGN-EB3: First Approval	77
Amivantamab: First Approval	76
Lonafarnib: First Approval	75
Fabry Disease: The Current Treatment Landscape	74
HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety	74
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review	71
Decitabine/Cedazuridine: First Approval	70
Deucravacitinib: First Approval	70
Pralsetinib: First Approval	69
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder	69
Remimazolam: A Review in Procedural Sedation	68
Belzutifan: First Approval	67
Savolitinib: First Approval	66
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases	65
Inebilizumab: First Approval	64
Faricimab: First Approval	64
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19	60
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations	60
Tisotumab Vedotin: First Approval	60
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	58
Casirivimab/Imdevimab: First Approval	58
Vutrisiran: First Approval	57
Abrocitinib: First Approval	57
Disitamab Vedotin: First Approval	57
Molnupiravir: First Approval	57
Telitacicept: First Approval	55
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain	55
Infigratinib: First Approval	55